XRCC1 rs25487: DNA Repair & Pharmacogenomics
The rs25487 single nucleotide polymorphism is a widely studied coding variant in the XRCC1 gene, resulting in an amino acid change from arginine to glutamine at codon 399 (Arg399Gln). It has been extensively investigated for its role in modulating base excision repair efficiency and influencing clinical outcomes following DNA-damaging cytotoxic chemotherapies and radiation therapy. Because findings across clinical studies remain mixed and population-specific, its pharmacogenomic evidence strength is currently considered limited.
What each genotype means
Potential increased platinum response
Research suggests that individuals with the GG genotype may experience an increased response when treated with platinum-based chemotherapy compared to those with the A allele. However, evidence is conflicting and clinical outcomes are influenced by many other genetic and environmental factors. Please discuss your treatment plan and potential medication responses with your oncologist or pharmacist.
This genotype is common in many global populations, though its frequency varies significantly by ancestry.
Variable treatment response profile
This genotype represents a heterozygous state for the XRCC1 variant. Studies on how this specific combination affects DNA repair capacity and chemotherapy response have yielded inconsistent results across different cancer types. You should consult with your healthcare provider regarding how this genetic information might relate to your specific clinical situation.
This is a frequently observed genotype in most populations worldwide.
Potential decreased platinum response
Some studies indicate that individuals with the AA genotype may have a decreased response to certain platinum-based therapies compared to those with the G allele. Because research findings are inconsistent and often depend on the specific type of cancer and treatment regimen, this result should not be used to make independent medical decisions. Always discuss your therapeutic options and potential drug responses with your clinical team.
This genotype is common in many populations and is particularly prevalent in certain South Asian cohorts.
What is rs25487 and Where is it Located?
The single nucleotide polymorphism rs25487 is located on chromosome 19 (19q13) within the tenth exon of the X-ray repair cross-complementing group 1 (XRCC1) gene. At the molecular sequence level, the variant typically manifests as a transition between guanine and adenine (G>A on the positive strand, or C>T depending on the reported reference transcript). This base substitution alters the codon 399 sequence from CGG to CAG, triggering a missense amino acid change from arginine (Arg) to glutamine (Gln). The alteration occurs in a linker region between the functional catalytic domains of the protein, near its interaction sites. Because rs25487 changes an amino acid in a vital maintenance protein, it has attracted substantial attention in molecular epidemiology and pharmacogenomic research for decades.
The Biological Role of the XRCC1 Protein
The XRCC1 protein acts as an indispensable scaffolding coordinator in the cellular base excision repair (BER) pathway and single-strand break repair systems. While XRCC1 has no intrinsic catalytic enzymatic activity, it serves as a central hub that physically stabilizes and coordinates critical repair partners, such as DNA polymerase beta (POLB), DNA ligase III, and poly(ADP-ribose) polymerase (PARP). When cellular DNA is damaged by oxidative stress, alkylating chemicals, or ionizing radiation, the XRCC1 scaffold ensures that fragmented base lesions and single-strand breaks are excised and sealed correctly. Alterations in its amino acid structure, such as the Arg399Gln substitution, have been reported in functional cell assays to decrease DNA repair efficiency, leading to higher levels of chromosomal breaks or baseline genetic instability.
Pharmacogenomic Impact and Evidence Strength
Because many cancer treatments intentionally kill tumor cells by causing severe DNA damage, cellular repair capacity influences treatment response. Cytotoxic regimens involving platinum compounds (such as cisplatin, carboplatin, and oxaliplatin), alkylating agents (such as cyclophosphamide), and radiotherapy depend on overwhelming repair pathways. Researchers hypothesized that the reduced repair capacity linked to the 399Gln (A) allele would improve tumor kill, but clinical data have revealed conflicting outcomes: some cohorts show heightened clinical response, whereas others exhibit increased treatment toxicity or drug resistance. Clinical consortia like CPIC have not established actionable dosing guidelines for rs25487. Consequently, the pharmacogenomic evidence strength remains categorized as limited and investigational rather than definitively predictive.
Understanding Ancestry and Population Frequencies
The alleles of rs25487 are distributed widely around the globe, but their prevalence differs substantially by geographic and ancestral background. In global reference aggregations like gnomAD, the minor allele frequency (MAF) sits around 0.35. However, cohort-level analyses show dramatic regional shifts. In many South Asian cohorts, the variant allele occurs at high frequencies, often presenting an allele count exceeding 0.80 or high carrier status in regional surveys. In contrast, European and East Asian cohorts demonstrate intermediate allele distributions, whereas certain African populations exhibit distinctive haplotype patterns. Because background genetics and environmental exposures vary widely, association findings from one population rarely generalize directly to another.
What You Can and Cannot Do with This Information
Learning your rs25487 genotype provides educational insight into your baseline cellular DNA repair genetics, but it cannot be used to diagnose any disease or predict how you will respond to medication. This variant is a low-penetrance, susceptibility-modifying factor rather than a deterministic disease gene. It does not replace clinical evaluation or established therapeutic biomarkers. If you are undergoing chemotherapy, radiotherapy, or evaluating prescription medicines, never attempt to adjust dosages, switch medications, or refuse therapy based on direct-to-consumer genetic findings. Any medical choices regarding cancer therapies or drug regimens must be reviewed directly with your oncologist, treating physician, or clinical pharmacist.
How common is this variant?
The minor allele frequency (MAF) of rs25487 is approximately 0.35 across global populations, though allele frequencies vary significantly by ancestry and can exceed 0.80 in specific South Asian cohorts.
Frequently asked questions
Does having the rs25487 AA genotype mean my chemotherapy will fail?
No. Having the AA genotype does not mean chemotherapy will fail. Studies investigating rs25487 and cytotoxic drug outcomes have reported mixed results across various cancer types, and clinical guidelines do not use this variant to select or modify treatment.
Can rs25487 be used to diagnose cancer or another disease?
No, rs25487 cannot diagnose cancer or any other condition. It is a common single nucleotide polymorphism that acts as a low-penetrance modifier, not a causative, high-risk disease mutation.
Should I ask my doctor to change my drug dosage based on rs25487?
You should never change your medication dosing based on rs25487 results. There are currently no CPIC or FDA guidelines recommending dosage changes for this variant, so any dosing decisions must remain in the hands of your treating physician or clinical pharmacist.
Why do different scientific studies report conflicting results for rs25487?
Conflicting findings arise because DNA repair involves redundant biochemical pathways, complex gene-environment interactions, and varied cancer types. Additionally, different ancestral genetic backgrounds and small cohort sizes can lead to divergent statistical associations between studies.
Sources & further reading
Educational information only, last refreshed 9/5/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs25487?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29